{
    "nctId": "NCT01199432",
    "briefTitle": "Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer",
    "officialTitle": "A Phase \u2163 Randomized Clinical Trial of Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 501,
    "primaryOutcomeMeasure": "Pathologic complete response \uff08PCR\uff09",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients, age \u2266 65 years old\n* Histologically or cytologically confirmed primary breast cancer by core biopsy\n* Disease stage appropriate for neoadjuvant chemotherapy (T2\uff5eT3\uff0cN0\uff5e2\uff0cM0)\n* No previous treatment for breast cancer\n* No history of other malignancies\n* No currently uncontrolled diseased (e.g., ongoing cardiac dysrhythmias, unstable diabetes) or active infection\n* No history of other malignancies\n* No currently uncontrolled diseased or active infection\n* Not pregnant or breast feeding, and on appropriate birth control if of child-bearing potential\n* Adequate cardiovascular function reserve without a myocardial infarction within the past six month\n* Adequate hematologic function with:\n\n  1. Absolute neutrophil count (ANC) \u2265 1500/mm3\n  2. Platelets \u2265 100,000/ mm3\n  3. Hemoglobin \u2265 10 g/dL\n* Adequate hepatic and renal function with:\n\n  1. Serum bilirubin \u2264 1.5\u00d7UNL\n  2. Alkaline phosphatase and alanine aminotransferase (ALT) \u2264 2.5 x ULN.\n  3. Serum creatinine \u2264 1.7 mg/dl\n* Knowledge of the investigational nature of the study and Ability to give informed consent\n* Ability and willingness to comply with study procedures\n\nExclusion Criteria:\n\n* Known or suspected distant metastases\n* Concurrent malignancy or history of other malignancy\n* Uncontrolled diseases or active infection\n* Hepatic or renal dysfunction as detailed above\n* Geographical, social, or psychological problems that would compromise study compliance\n* Known or suspected hypersensitivity to cyclophosphamide, epirubicin and fluorouracil",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}